Wells Fargo & Company Reaffirms Overweight Rating for MorphoSys (NASDAQ:MOR)

Wells Fargo & Company reaffirmed their overweight rating on shares of MorphoSys (NASDAQ:MOR – Free Report) in a report issued on Monday, Benzinga reports. They currently have a $17.00 price objective on the stock. Several other analysts also recently commented on MOR. Leerink Partnrs restated a market perform rating on shares of MorphoSys in a […]

Related Keywords

United States ,Leerink Partnrs ,Wells Fargo Company ,Sigma Securities ,Qube Research Technologies Ltd ,Jpmorgan Chase Co ,Nasdaq ,Morphosys Company Profile ,Virtu Financial ,Morgan Stanley ,Goldman Sachs Group ,Wells Fargo ,Free Report ,Moderate Buy ,Get Free Report ,Technologies Ltd ,Two Sigma Securities ,Morphosys Daily ,Morphosys ,Nasdaq Mor ,Humor ,Medical ,Reiterated Rating ,